COMPANY

Zylo Therapeutics

HQ: Greenville, SC source · zylotherapeutics.com ↗ · Southeast

Location: Greenville, SC · source · Oct 15, 2026

Profile checked Oct 10, 2026

8NIH grants

Funding and NIH signals

NIH award NIH awarded $300K (STTR Phase I 5R41AI188793-02, continuation, notice Sep 2, 2026). NIH RePORTER 5R41AI188793-02 (Sep 2, 2026)
Evidence (1 event)
- Sep 2, 2026 · NIH RePORTER 5R41AI188793-02
  Organization: ZYLO THERAPEUTICS, INC.; City/State: GREENVILLE, SC; Project number: 5R41AI188793-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 2, 2026 Grant Government grant — STTR: $300,000 (annual award, as published), announced Sep 2, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 12, 2025 Grant Government grant — STTR: $300,000 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Sep 2, 2026 Government grant — STTR: $300,000 (annual award, as published), announced Sep 2, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 12, 2025 Government grant — STTR: $300,000 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 8

Annual award amounts. Total $3.1M.

Jul 18, 2024 NIH award 5R41AR082749-02 FY2024: $145,888 awarded for that fiscal year; activity R41 (STTR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Development of an endocannabinoid m source ↗
Jul 17, 2023 NIH award 5R41AI165204-02 FY2023: $300,000 awarded for that fiscal year; activity R41 (STTR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Development and optimization of a n source ↗
May 25, 2023 NIH award 1R41AR082749-01 FY2023: $147,861 awarded for that fiscal year; activity R41 (STTR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Development of an endocannabinoid m source ↗
Sep 12, 2022 NIH award 1R41DK129147-01A1 FY2022: $263,446 awarded for that fiscal year; activity R41 (STTR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Optimization of a nanoparticle-ba source ↗
Aug 18, 2022 NIH award 1R41AI165204-01A1 FY2022: $300,000 awarded for that fiscal year; activity R41 (STTR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Development and optimization of a source ↗
Jul 25, 2022 NIH award 5R44DK121587-03 FY2022: $1,008,058 awarded for that fiscal year; activity R44 (SBIR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Development of microparticle-base source ↗
Jul 19, 2021 NIH award 2R44DK121587-02 FY2021: $697,168 awarded for that fiscal year; activity R44 (SBIR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Development of microparticle-based source ↗
Sep 13, 2019 NIH award 1R41DK121587-01 FY2019: $225,000 awarded for that fiscal year; activity R41 (STTR); PI DRAGANSKI, ANDREW R; recipient as written: ZYLO THERAPEUTICS, INC., GREENVILLE, SC. Optimization of microparticle-based source ↗